“IDeate-Prostate01 marks the initiation of the third pivotal trial in the ifinatamab deruxtecan development program and reinforces our commitment to addressing critical unmet needs for patients ...

IDeate-Prostate01 is a multicenter, open-label, randomized phase 3 trial evaluating the safety and efficacy of ifinatamab deruxtecan (12 mg/kg) versus docetaxel (75 mg/m 2) plus corticosteroid in ...

In these gaps, we have discovered that systems don’t quite align, and people end up navigating workarounds instead of actual ...

Vidhya Subramanian redefines classical dance with 'Damaru', showcasing tradition and innovation in a changing world.

Priyanka Jain, CEO of Evvy, wants an employee who can not only strategize, but also execute. At a startup, she says, ...

AI can transform relationships throughout the client lifecycle, allowing humans to focus on deeper connections and sustained ...

"Following the promising results seen in our earlier phase trial, IDeate-Prostate01 has been initiated to evaluate whether ifinatamab deruxtecan may replace standard taxane-based chemotherapy as a ...

A test of the app Dia illustrates that the humble web browser may be the path to making artificial intelligence more natural ...

BASKING RIDGE, N.J. & RAHWAY, N.J., June 18, 2025--The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 clinical trial to evaluate the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with ...